Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: Synthesis, biological evaluation, and protein-ligand X-ray crystal structure

Journal of Medicinal Chemistry

Volumn 54, Issue 16, 2011, Pages 5890-5901

  Ghosh, Arun K ^a   Chapsal, Bruno D ^a   Parham, Garth L ^a   Steffey, Melinda ^a   Agniswamy, Johnson ^b   Wang, Yuan Fang ^b   Amano, Masayuki ^c   Weber, Irene T ^b   Mitsuya, Hiroaki ^c,d  

^a PURDUE UNIVERSITY   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYHEXAHYDRO 2H CYCLOPENTA[B]FURAN 5 YL [3 HYDROXY 4 (N ISOBUTYL 4 METHOXYPHENYLSULFONAMIDO) 1 PHENYLBUTAN 2 YL]CARBAMATE; AMIDE; CARBONYL DERIVATIVE; CYCLOPENTANE DERIVATIVE; GLYCINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HYDROXYL GROUP; LIGAND; PROTEINASE INHIBITOR; SULFONAMIDE; UNCLASSIFIED DRUG; URETHAN DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGAND BINDING; MULTIDRUG RESISTANCE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; BINDING SITES; BIOCATALYSIS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; URETHANE;

EID: 80051884766     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200649p     Document Type: Article

References (33)

1. Palella, F. J., Jr.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection N. Engl. J. Med. 1998, 338, 853-860 (Pubitemid 28135961)
2. Sepkowitz, K. A. AIDSe - The First 20 Years N. Engl. J. Med. 2001, 344, 1764-1772
3. Gupta, R.; Hill, A.; Sawyer, A. W.; Pillay, D. Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials Clin. Infect. Dis. 2008, 47, 712-722
4. Wainberg, M. A.; Friedland, G. Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance JAMA, J. Am. Med. Assoc. 1998, 279, 1977-1983 (Pubitemid 28298277)
5. Ghosh, A. K.; Chapsal, B. D.; Weber, I. T.; Mitsuya, H. Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance Acc. Chem. Res. 2008, 41, 78-86
6. Ghosh, A. K.; Sridhar, P. R.; Kumaragurubaran, N.; Koh, Y.; Weber, I. T.; Mitsuya, H. Bis-Tetrahydrofuran: A Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance ChemMedChem. 2006, 1, 939-950 (Pubitemid 44448791)
7. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y.-F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel Bis-tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus in Vitro Antimicrob. Agents Chemother. 2003, 47, 3123-3129 (Pubitemid 37229567)
8. Ghosh, A.; Chapsal, B.; Mitsuya, H. In Aspartic Acid Proteases as Therapeutic Targets; Ghosh, A., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2010; pp 245-262.
9. Ghosh, A. K.; Dawson, Z. L.; Mitsuya, H. Darunavir, a Conceptually New HIV-1 Protease Inhibitor for the Treatment of Drug-Resistant HIV Bioorg. Med. Chem. Lett. 2007, 15, 7576-7580 (Pubitemid 47575929)
10. Ghosh, A. K.; Sridhar, P. R.; Leshchenko, S.; Hussain, A. K.; Li, J.; Kovalevsky, A. Y.; Walters, D. E.; Wedekind, J. E.; Grum-Tokars, V.; Das, D.; Koh, Y.; Maeda, K.; Gatanaga, H.; Weber, I. T.; Mitsuya, H. Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance J. Med. Chem. 2006, 49, 5252-5261 (Pubitemid 44260221)
11. Ghosh, A. K.; Leshchenko-Yashchuk, S.; Anderson, D. D.; Baldridge, A.; Noetzel, M.; Miller, H. B.; Tie, Y. F.; Wang, Y.-F.; Koh, Y.; Weber, I. T.; Mitsuya, H. Design of HIV-1 Protease Inhibitors with Pyrrolidinones and Oxazolidinones as Novel P1Ligands To Enhance Backbone-Binding Interactions with Protease: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies J. Med. Chem. 2009, 52, 3902-3914
12. Koh, Y.; Das, D.; Leschenko, S.; Nakata, H.; Ogata-Aoki, H.; Amano, M.; Nakayama, M.; Ghosh, A. K.; Mitsuya, H. GRL-02031, a Novel Nonpeptidic Protease Inhibitor (PI) Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant Human Immunodeficiency Virus Type 1 in Vitro Antimicrob. Agents Chemother. 2009, 53, 997-1006
13. Deardorff, D. R.; Windham, C. Q.; Craney, C. L. Org. Synth., Collect. Vol. 1998, 9, 487
14. Ghosh, A. K.; Chapsal, B. D.; Baldridge, A.; Ide, K.; Koh, Y.; Mitsuya, H. Design and Synthesis of Stereochemically Defined Novel Spirocyclic P2-Ligands for HIV-1 Protease Inhibitors Org. Lett. 2008, 10, 5135-5138
15. Hays, D. S.; Fu, G. C. Organotin Hydride Catalyzed Carbon-Carbon Bond Formation: Radical-Mediated Reductive Cyclization of Enals and Enones J. Org. Chem. 1996, 61, 4-5 (Pubitemid 126590474)
16. Bueno, J. M.; Coterón, J. M.; Chiara, J. L.; Fernández- Mayoralas, A.; Fiandor, J. M.; Valle, N. Stereoselective Synthesis of the Antifungal GM222712 Tetrahedron Lett. 2000, 41, 4379-4382 (Pubitemid 30414428)
17. Ghosh, A. K.; Chapsal, B. D.; Baldridge, A.; Steffey, M. P.; Walters, D. E.; Koh, Y.; Amano, M.; Mitsuya, H. Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P2 Ligands: Structure-Activity Studies and Biological Evaluation J. Med. Chem. 2011, 54, 622-634
18. Toth, M. V.; Marshall, G. R. A Simple Continuous Fluorometric Assay for HIV Protease Int. J. Pept. Protein Res. 1990, 36, 544-550
19. Ghosh, A. K.; Kulkarni, S.; Anderson, D. D.; Hong, L.; Baldridge, A.; Wang, Y.-F.; Chumanevich, A. A.; Kovalevsky, A. Y.; Tojo, Y.; Amano, M.; Koh, Y.; Tang, J.; Weber, I. T.; Mitsuya, H. Design, Synthesis, Protein-Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors To Combat Drug Resistance J. Med. Chem. 2009, 52, 7689-7705
20. Kovalevsky, A. Y.; Liu, F.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. Ultra-High Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114 J. Mol. Biol. 2006, 363, 161-173 (Pubitemid 44437563)
21. Gustchina, A.; Sansom, C.; Prevost, M.; Richelle, J.; Wodak, S. Y.; Wlodawer, A.; Weber, I. T. Energy Calculations and Analysis of HIV-1 Protease-Inhibitor Crystal Structures Protein Eng. 1994, 7, 309-316
22. Tie, Y.; Boross, P. I.; Wang, Y. F.; Gaddis, L.; Liu, F.; Chen, X.; Tozser, J.; Harrison, R. W.; Weber, I. T. Molecular Basis for Substrate Recognition and Drug Resistance from 1.1 to 1.6 : Resolution Crystal Structures of HIV-1 Protease Mutants with Substrate Analogs FEBS J. 2005, 272, 5265-5277 (Pubitemid 41503156)
23. Mahalingam, B.; Louis, J. M.; Hung, J.; Harrison, R. W.; Weber, I. T. Structural Implications of Drug-Resistant Mutants of HIV-1 Protease: High Resolution Crystal Structures of the Mutant Protease/Substrate Analog Complexes Proteins 2001, 43, 455-464 (Pubitemid 32476440)
24. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Macromolecular Crystallography, Part A; Carter, C. W., Jr.; Sweet, R. M., Eds.; Methods in Enzymology, Vol. 276; Academic Press: San Diego, CA, 1997; pp 307-326. (Pubitemid 27085611)
25. Shen, C. H.; Wang, Y. F.; Kovalevasky, A. Y.; Harrison, R. W.; Weber, I. T. Amprenavir Complexes with HIV-1 Protease and Its Drug-Resistant Mutants Altering Hydrophobic Clusters FEBS J. 2010, 277 (18) 3699-3714
26. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser Crystallographic Software J. Appl. Crystallogr. 2007, 40, 658-674 (Pubitemid 47080256)
27. Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr., 1994, 50, 760-763.
28. Potterton, E.; Briggs, P.; Turkenburg, M.; Dodson, E. A Graphical User Interface to the CCP4 Program Suite Acta Crystallogr., Sect. D: Biol. Crystallogr. 2003, 59, 1131-1137 (Pubitemid 36872348)
29. Sheldrick, G. M. A Short History of SHELX Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112-122
30. Sheldrick, G. M.; Schneider, T. R. SHELXL: High Resolution Refinement Methods Enzymol. 1997, 277, 319-343
31. Emsley, P.; Cowtan, K. Coot: Model-Building Tools for Molecular Graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132 (Pubitemid 41742764)
32. Schuettelkopf, A. W.; van Aalten, D. M. F. PRODRG: A Tool for High-Throughput Crystallography of Protein-Ligand Complexes Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363 (Pubitemid 41079731)
33. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 (Pubitemid 30047768)